Overview

Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20)

Status:
Completed

Trial end date:
2016-03-01

Target enrollment:

Participant gender:

Summary

To evaluate tolerance to and efficacy of bevacizumab in the treatment of MCRC in elderly patients, we propose a phase II randomised study comparing a chemotherapy + bevacizumab arm with a chemotherapy alone arm in the first-line treatment of MCRC in patients aged 75 years and older. This study is destined to continue as a phase III trial if both arms meet the selection criteria to show or not the benefits of treatment with bevacizumab combined with chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

Centre Hospitalier Universitaire Dijon

Treatments:

Bevacizumab
Fluorouracil
Leucovorin
Oxaliplatin